SonoThera secured an oversubscribed $125 million Series B to move its ultrasound-mediated genetic medicine platform into clinical development. The company framed the round as funding for two lead programs in Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. The financing expands capital available for non-viral gene delivery, an approach aimed at reducing the delivery constraints seen with viral vectors. SonoThera’s ultrasound platform is intended to support gene transfer in vivo by coupling targeted delivery with genetic payload administration. The raise adds momentum to ultrasound-based delivery as a competitor modality in gene therapy development, with investors continuing to back platform companies that can scale across multiple indications.